Vivos Therapeutics, Inc.
VVOS
$2.57
$0.000.00%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 0.54% | -9.23% | -17.70% | -13.87% | -11.93% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.54% | -9.23% | -17.70% | -13.87% | -11.93% |
| Cost of Revenue | -6.18% | -8.72% | -14.61% | -7.91% | 3.68% |
| Gross Profit | 5.19% | -9.57% | -19.72% | -17.45% | -20.26% |
| SG&A Expenses | -22.73% | -27.89% | -28.15% | -27.41% | -24.27% |
| Depreciation & Amortization | -8.72% | -11.54% | -12.92% | -6.89% | -3.75% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -19.71% | -24.49% | -25.80% | -24.34% | -19.65% |
| Operating Income | 34.99% | 35.72% | 31.42% | 31.02% | 24.64% |
| Income Before Tax | 18.46% | 35.77% | 22.63% | 43.04% | 38.72% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 18.46% | 35.77% | 22.63% | 43.04% | 38.72% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 18.46% | 35.77% | 22.63% | 43.04% | 38.72% |
| EBIT | 34.99% | 35.72% | 31.42% | 31.02% | 24.64% |
| EBITDA | 35.90% | 36.50% | 31.60% | 31.68% | 25.19% |
| EPS Basic | 58.20% | 61.46% | 49.37% | 57.81% | 53.50% |
| Normalized Basic EPS | 58.26% | 61.50% | 49.42% | 60.14% | 54.26% |
| EPS Diluted | 58.17% | 61.45% | 49.36% | 57.81% | 53.50% |
| Normalized Diluted EPS | 58.26% | 61.50% | 49.42% | 60.14% | 54.26% |
| Average Basic Shares Outstanding | 200.30% | 95.46% | 60.13% | 30.50% | 30.27% |
| Average Diluted Shares Outstanding | 200.30% | 95.46% | 60.13% | 30.50% | 30.27% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
